Approval · Notice of Compliance 5444 · 1994
SERZONE: Notice of Compliance 5444
Issued April 27, 1994
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 5444
- Date
- April 27, 1994
- Company
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Antidepressant
Products in this notice
Medicinal ingredients
- NEFAZODONE HCL 50 MG per TAB
- NEFAZODONE HCL 100 MG per TAB
- NEFAZODONE HCL 200 MG per TAB
- NEFAZODONE HCL 300 MG per TAB
- NEFAZODONE HCL 150 MG per TAB